Elanco Animal Health Inc

Latest Results (20.08.2024):

Revenue Growth

Elanco Animal Health Inc. reported revenue of $1,184 million for the second quarter of 2024, marking a 12% increase on a reported basis compared to the same period in 2023. When excluding the unfavorable impact of foreign exchange rates, the revenue growth was 13%. This growth was significantly influenced by the ERP Blackout, which positively impacted the growth by an estimated 9% to 10%.

Net Loss and Adjusted Income

For the second quarter of 2024, Elanco Animal Health Inc. reported a net loss of $50 million. However, the adjusted net income was significantly higher at $147 million. This adjustment reflects the company's efforts to manage its financial performance amidst various operational challenges and market conditions.

Adjusted EBITDA

Elanco Animal Health Inc. achieved an adjusted EBITDA of $275 million in the second quarter of 2024, which represents 23.2% of the total revenue. This is a notable increase from the previous year's adjusted EBITDA of $222 million, indicating a 24% year-over-year growth. The improvement in adjusted EBITDA underscores the company's operational efficiency and cost management strategies.

EPS Performance

In the second quarter of 2024, Elanco Animal Health Inc. reported an earnings per share (EPS) of $(0.10) on a reported basis. However, the adjusted EPS was $0.30, showing a significant improvement from the adjusted EPS of $0.18 in the second quarter of 2023. This 67% increase in adjusted EPS highlights the company's enhanced profitability and financial health.

Full Year Guidance

Elanco Animal Health Inc. has updated its full-year 2024 financial guidance, reflecting the divestiture of its aqua business and expected contributions from new products like Bovaer and Zenrelia. The company now anticipates revenue between $4,410 million and $4,460 million, with organic constant currency growth raised to 3% to 4%. Additionally, the adjusted EBITDA is projected to be between $900 million and $940 million, with an adjusted EPS ranging from $0.88 to $0.96.